Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?
Web of Science
AuthorBrinkmann, K; Kashkar, H
Source TitleCell Death and Disease
PublisherSpringer Science and Business Media LLC
University of Melbourne Author/sBrinkmann, Kerstin
AffiliationMedical Biology (W.E.H.I.)
Document TypeJournal Article
CitationsBrinkmann, K. & Kashkar, H. (2014). Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?. Cell Death Dis, 5 (3), pp.e1098-. https://doi.org/10.1038/cddis.2014.61.
Access StatusOpen Access
Open Access at PMChttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973243
Acquired resistance toward apoptosis represents one of the hallmarks of human cancer and a major cause of the inefficacy of most anticancer treatment regimens. Based on its ability to inhibit apoptosis, the B-cell lymphoma/leukemia 2 (Bcl-2) protein family has garnered the most attention as a promising therapeutic target in cancer. Accordingly, efforts have lately been focused on the development of drugs targeting Bcl-2 proteins with considerable therapeutic success, particularly in hematologic malignancies. Here, we review the previous studies and highlight the pivotal role of the Bcl-2 protein family in the homeostasis of hematologic tissue compartment. This knowledge provides more insight into why some cancers are more sensitive to Bcl-2 targeting than others and will foster the clinical evaluation of Bcl-2-targeting strategies in cancer by avoiding severe on-target side effects in the development of healthy tissues.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References